TY - JOUR
T1 - Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
JO - BMJ Open
UR - http://dx.doi.org/10.1136/bmjopen-2023-083582
PY - 2024/02/05
AU - Brittain G
AU - Petrie J
AU - Duffy KEM
AU - Glover R
AU - Hullock K
AU - Papaioannou D
AU - Roldan E
AU - Beecher C
AU - Bursnall M
AU - Ciccarelli O
AU - Coles AJ et al
ED -
DO - DOI: 10.1136/bmjopen-2023-083582
PB - BMJ
VL - 14
IS - 2
SP - e083582
EP - e083582
Y2 - 2025/03/15
ER -